Can patients with myeloma take ixazomib for a long time?

Whether patients with myeloma can take ixazomib for a long time is a question involving many factors.

Ixazomib is an oral proteasome inhibitor that blocks the protein degradation process in tumor cells by inhibiting the chymotrypsin-like activity of the 20S proteasome, affecting cell proliferation and apoptosis regulation, thereby inhibiting tumor growth. Multiple clinical trials have shown that ixazomib combined with lenalidomide and dexamethasone (IRd regimen) has demonstrated significant efficacy in the treatment of multiple myeloma (MM). For example, the TOURMALINE-MM1 study showed that the IRd regimen significantly improved patients’ progression-free survival (PFS) and prolonged overall survival (OS). In addition, ixazomib also showed good therapeutic effects in patients with high-risk cytogenetics, and the median progression-free survival was similar to that of the overall population.

The recommended starting dose of ixazomib is 4 mg per session on day 28 of the treatment cycle 1, 8 and 15 days of administration, that is, administration 1 times per week. Patients should take it at least 1 hour before a meal or at least 2 hours after a meal to ensure optimal absorption of the drug. Also, take the entire capsule with water and do not crush, chew, or open the capsule. This method of administration is simple and easy to implement, which is helpful for patients to take it by themselves at home and improves treatment compliance.

Although ixazomib has shown remarkable efficacy in the treatment of multiple myeloma, its safety is also an important issue of concern to patients and doctors. Adverse reactions of ixazomib include hematological toxicity (such as thrombocytopenia, neutropenia), gastrointestinal toxicity (such as diarrhea, nausea, vomiting), skin toxicity (such as rash), peripheral neuropathy, etc. Most adverse reactions are mild to moderate and can be alleviated by dose adjustment or symptomatic treatment. However, for serious adverse reactions, such as allergic reactions, reversible posterior encephalopathy syndrome, etc., the drug should be discontinued immediately and seek medical treatment.

Myeloma patients vary in their response to medications depending on the severity of their disease. For patients with milder disease, a smaller dose may be required; for patients with more severe disease, a larger dose may be required or combined with other medications. Therefore, when formulating a treatment plan, doctors will judge whether long-term use of ixazomib is needed based on the patient's specific condition.

Different patients tolerate medications differently. Some patients may tolerate treatment with ixazomib well, while others may experience serious adverse effects. For patients who experience serious adverse reactions, doctors may consider adjusting the dose or discontinuing the drug.

Multiple myeloma is a chronic disease that requires long-term control. Ixazomib is one of the effective drugs for the treatment of multiple myeloma, and its long-term medication consideration should be based on the patient's treatment goals and life expectancy. Long-term medication may be necessary for patients who wish to prolong survival and improve quality of life.

Whether patients with myeloma can take ixazomib for a long time needs to be comprehensively considered based on the patient's specific condition, drug tolerance, treatment goals, economic burden and other factors. Under the professional guidance of doctors, rational formulation of medication plans and close monitoring of patients' physical conditions and drug responses are the keys to ensuring patients' safe and effective medication use. At the same time, patients should also actively cooperate with the doctor's treatment suggestions and pay attention to their body's reaction in order to adjust the treatment plan in a timely manner.